Rajbhandari, RajaniMcFarland, Braden C.Patel, AshishGerigk, MagdaGray, KennethFehling, Samuel C.Bredel, MarkusBerbari, Nicolas F.Kim, HyunsooMarks, Margaret P.Meares, Gordon P.Sinha, TanviChuang, JeffreyBenveniste, Etty N.Nozell, Susan E.2023-09-192023-09-192015Rajbhandari R, McFarland BC, Patel A, et al. Loss of tumor suppressive microRNA-31 enhances TRADD/NF-κB signaling in glioblastoma. Oncotarget. 2015;6(19):17805-17816. doi:10.18632/oncotarget.4596https://hdl.handle.net/1805/35607Glioblastomas (GBMs) are deadly tumors of the central nervous system. Most GBM exhibit homozygous deletions of the CDKN2A and CDKN2B tumor suppressors at 9p21.3, although loss of CDKN2A/B alone is insufficient to drive gliomagenesis. MIR31HG, which encodes microRNA-31 (miR-31), is a novel non-coding tumor suppressor positioned adjacent to CDKN2A/B at 9p21.3. We have determined that miR-31 expression is compromised in >72% of all GBM, and for patients, this predicts significantly shortened survival times independent of CDKN2A/B status. We show that miR-31 inhibits NF-κB signaling by targeting TRADD, its upstream activator. Moreover, upon reintroduction, miR-31 significantly reduces tumor burden and lengthens survival times in animal models. As such, our work identifies loss of miR-31 as a novel non-coding tumor-driving event in GBM.en-USAttribution 4.0 InternationalNF-κBGlioblastomaTRADDmicroRNA-31Article